Latest Commercialization News

Sabre Resources has completed the sale of its Ninghan Gold Project to Capricorn Metals, receiving $1.85 million in initial consideration plus ongoing royalties and milestone payments.

FleetPartners Group Limited reported a 2.6% revenue increase to $377 million for the half-year ended March 2025, while net profit after tax declined 5.3% to $34.5 million, reflecting operational headwinds from a major system upgrade.

FBR Limited has completed the final tranche of its $6.3 million placement, enabling significant cost reductions and operational consolidation that position the company for a more sustainable future.

Nanoveu Limited has completed the first tranche of a $2.7 million capital raise, issuing over 61 million shares to bolster its advanced semiconductor and materials science ventures. Additional placements to executives and the Chairman are planned, pending shareholder approval.

TZ Limited has secured its inaugural purchase order for data centre cabinet locking kits from Wesco Anixter, acting on behalf of Microsoft, marking a significant commercial milestone after a successful pilot phase.

Chrysos Corporation has secured a landmark Master Services Agreement with Newmont Corporation, marking its first PhotonAssay unit deployment at the Ahafo mine in Ghana. This deal signals growing adoption of Chrysos’ cutting-edge gold analysis technology among top-tier miners.

Donaco International Limited has postponed its Scheme of Arrangement timetable amid extended legal and valuation reviews, while revealing a new 10% VAT gaming tax liability in Cambodia effective from January 2025.

Orthocell has rapidly expanded its US distributor network for Remplir™, surpassing its target ahead of schedule and positioning itself for imminent sales in the $1.6 billion nerve repair market.

Acrux Limited, partnering with TruPharma, has introduced its Dapsone 7.5% Gel in the US, featuring a unique tube packaging that aims to improve patient convenience and reduce environmental impact.

AVITA Medical reported a strong first quarter with revenues up 67% to $18.5 million, driven by expanded commercial sales and new product introductions. Despite a narrower net loss, the company faces ongoing challenges from revenue covenants and macroeconomic pressures.

AVITA Medical reveals a bold expansion plan targeting a $3.5 billion U.S. acute wound care market by 2025, driven by a multi-product portfolio and sustained revenue growth.

AVITA Medical reported a robust 67% increase in first quarter 2025 revenue, driven by new product launches and a strategic commercial overhaul, while reaffirming its full-year growth and profitability targets.